<DOC>
	<DOCNO>NCT00026949</DOCNO>
	<brief_summary>This study examine body handle etoposide , drug use treat breast cancer . The knowledge gain may lead effective use drug few side effect future . Breast cancer patient receive etoposide part treatment may participate study . Patients 18 blood sample ( teaspoon less ) draw 72-hour period infusion etoposide . The initial blood sample take intravenous line ( small tube place vein ) use deliver etoposide , second line may place temporarily obtain sample .</brief_summary>
	<brief_title>Study Etoposide Breast Cancer Patients</brief_title>
	<detailed_description>Etoposide topoisomerase II inhibitor broad range anticancer activity conventional dos ( 100 mg/m ( 2 ) daily x 5 day ) administer high dos ( great 1200 mg/m ( 2 ) ) component pre-transplant myeloablative chemotherapy regimen . Etoposide pharmacokinetics linear 30-fold dose range , disposition highly variable . Etoposide highly protein bound ( 95 % ) albumin , protein binding ( therefore free drug concentration ) vary widely cancer patient . Etoposide eliminate metabolism renal excretion , may also contribute variability . The pharmacokinetics etoposide studied patient receive high-dose etoposide part pre-transplant preparative regimen , pharmacokinetic parameter generate pharmacokinetic modeling correlate clinical laboratory characteristic toxicity order develop rational dosing method .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>INCLUSION CRITERIA Age great equal 18 year . Patients breast cancer enter exist Medicine Branch protocols include highdose etoposide . Must able provide inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>Etoposide</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>